This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy
Diabetology & Metabolic Syndrome Open Access 06 March 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 March 2017
In the version of this article initially published online, the original article reference details were incorrect. This error has been corrected for the HTML and PDF versions of the article.
References
Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. http://dx.doi.org/10.1016/j.jhep.2017.01.022 (2017)
Rights and permissions
About this article
Cite this article
Thomas, H. A critical role for the NLRP3 inflammasome in NASH. Nat Rev Gastroenterol Hepatol 14, 197 (2017). https://doi.org/10.1038/nrgastro.2017.21
Published:
Issue date:
DOI: https://doi.org/10.1038/nrgastro.2017.21
This article is cited by
-
Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy
Diabetology & Metabolic Syndrome (2025)